After 22 years at the National Cancer Institute (NCI) the last six as director Samuel Broder will retire in April to become chief scientific officer at IVAX Corp., a Miami-based pharmaceutical company, at a salary reported to be about twice his current pay of $120,000. There is more than money behind Broder's December decision to leave, however. His is a portrait of a scientist frustrated with the politics of government service and increasingly estranged from scientific colleagues, cancer patient advocates, and other constituencies.

Broder's legacy at NCI includes central work on the development of AZT, one of only a few drugs approved to directly treat HIV infection. He is also credited with broadly and effectively promoting the full range of basic and clinical research activities at NCI, the largest of the National Institutes of Health, with a budget of more than $2 billion.

"I view him as having been more...

Interested in reading more?

Become a Member of

Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member?